NeuBase Therapeutics Initiates Trading on NASDAQ Under Ticker Symbol “NBSE”
Rare genetic diseases collectively affect hundreds of millions of people worldwide
The next generation of gene silencing technology
NeuBase has developed a modular antisense peptide nucleic acid (PNA) platform with the capability to address rare genetic disease caused by mutant proteins with a single, cohesive approach. NeuBase has improved gene silencing therapies to include the advantages of synthetic approaches with the precision of antisense technologies.
Technology
The advantages of the NeuBase PATrOL™ platform enable the company to cohesively develop therapies for a wide range of rare genetic diseases, including repeat expansion disorders, dominant and recessive genetic disorders and cancers driven by specific oncogenic mutations.
NeuBase is first addressing Huntington’s disease and myotonic dystrophy.
The NeuBase technology has several advantages over traditional ASOs
Sd
Scalable & Modular Development
Pre-organized peptide backbone and toolkit of engineered nuclear bases allow drugs to be quickly snapped together for many targets
Ts
Targeting Secondary RNA Structures
Higher specificity for mutant over wild type transcript, allowing for fewer off-target effects and more effective deactivation of disease-related mRNA
Sa
Systemic Administration
Ability to cross the blood brain barrier and disseminate broadly, allowing for systemic administration in neurological indications
Ni
No Immune Response
Do not cause an immune response when systemically administered, enabling us to develop solutions for pre-symptomatic individuals who are gene positive
News & Views
NeuBase Therapeutics Closes Merger Transaction with Ohr Pharmaceutical
NeuBase Therapeutics to Participate in Roth RNA Revolution Conference
NeuBase Therapeutics to Present at the LD Micro Conference
NeuBase Therapeutics Initiates Trading on NASDAQ Under Ticker Symbol “NBSE”
PITTSBURGH, July 15, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” and the “Company”), a biotechnology company developing next generation antisense therapies to address genetic diseases, announced today that its common stock began trading on The Nasdaq Capital Market under the ticker symbol “NBSE” at the open of market trading today, July 15, 2019, and will cease using the previous ticker symbol, “OHRP”.
NeuBase Therapeutics Closes Merger Transaction with Ohr Pharmaceutical
Company expects to initiate trading on NASDAQ Under Ticker Symbol “NBSE” effective July 15, 2019
Company completes previously announced financing of approximately $9 million immediately prior to closing of the merger
Greenlight Capital agrees to purchase ~9% of NeuBase Therapeutics common stock in a private placement immediately following the merger closing
NeuBase Therapeutics to Participate in Roth RNA Revolution Conference
PITTSBURGH, July 11, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (“NeuBase”), a biotechnology company developing next generation antisense therapies to address genetic diseases, today announced that Dietrich Stephan, Ph.D., NeuBase’s chief executive officer, will participate in two panel discussions as well as 1x1 meetings with investors at the Roth RNA Revolution Conference being held in New York City on July 17, 2019.
NeuBase Therapeutics to Present at the LD Micro Conference
PITTSBURGH, June 05, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (“NeuBase”), a biotechnology company developing next generation antisense therapies to address genetic diseases, announced today that Dietrich Stephan, Chief Executive Officer, will present a corporate overview and business update at the LD Micro 9th Annual Invitational, being held at the Luxe Sunset Boulevard Hotel in Los Angeles, California.